Ryan Levenhagen, DO
Hospitalist · Chicago, ILNPI 1609289040
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 29.4% of the total. Reporting peaked in 2019 at $1,320 and has fallen 70.7% since, to $386 in 2025. Among hospitalist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$489
- Pfizer$486
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$466
- Gilead$271
- Boehringer Ingelheim$232
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,209100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,237 |
| Novo Nordisk | 32 | $489 |
| Pfizer | 21 | $486 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $466 |
| Gilead | 15 | $271 |
| Boehringer Ingelheim | 12 | $232 |
| Amgen(2 entities) | 14 | $217 |
| Avanir Pharmaceuticals, Inc. | 6 | $129 |
| Johnson & Johnson | 6 | $121 |
| Radius Health, Inc. | 5 | $94 |
| Merck | 7 | $94 |
| Astellas Pharma US Inc | 3 | $65 |
| Lilly USA, LLC | 4 | $49 |
| Genentech USA, Inc. | 2 | $46 |
| Bausch Health US, LLC | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| GSK | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Coopersurgical, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$121
How this compares
$4,209 in reported general payments places this provider in the 95th percentile of 1,328 hospitalist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $41,693 |
| XareltoRivaroxaban | 32 | $6,653 |
| TradjentaLinagliptin | 19 | $5,082 |
| Scopolamine | 32 | $1,998 |
| Ethosuximide | 12 | $1,816 |
| Levetiracetam | 46 | $1,787 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $1,719 |
| LithostatAcetohydroxamic Acid | 16 | $1,708 |
| Atorvastatin Calcium | 59 | $1,448 |
| Mirtazapine | 24 | $1,327 |
| Diltiazem Hcl | 13 | $1,305 |
| Gabapentin | 50 | $1,159 |
| Lidocaine | 13 | $1,069 |
| Pantoprazole Sodium | 28 | $859 |
| Losartan Potassium | 41 | $811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $486 | $41,693153 claims |
| Johnson & JohnsonXarelto | $121 | $6,65332 claims |
| Boehringer IngelheimTradjenta | $232 | $5,08219 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $80811 claims |
| Lilly USA, LLCHumalog | $49 | $71015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,328 hospitalist providers in Illinois.
Other hospitalist in Chicago
- Salih SamoChicago$251K
- Eric GluckChicago$80K
- Alvin ThomasChicago$28K
- Tasmeen HussainChicago$18K
- Ronnie MandalChicago$10K
- Bobby DiniotisChicago$9K
- Nael GharbiChicago$8K
- Keith SummaChicago$7K
- Alicia RauhChicago$6K
- Anish MunagalaChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.